Stimuliver is developing a subcutaneous liver implant that utilizes lab-engineered liver tissue derived from human stem cells to supplement liver function in patients with severe liver disease. This technology provides a renewable treatment option, reducing reliance on donor organs and addressing the critical shortage of available transplants.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with severe liver disease often face a critical shortage of donor organs for transplantation, which is a major limitation in addressing their condition. Current treatment options are often insufficient to fully restore liver function, leading to significant morbidity and mortality.
Solution
Stimuliver is developing a subcutaneous liver implant that uses lab-engineered liver tissue derived from human stem cells to supplement liver function, offering a renewable treatment option independent of donor organs. The implant is designed to filter toxins and reduce the burden on the native liver, providing a radically different approach to liver disease management. This off-the-shelf, automated, and scalable design aims to safely supplement liver function through remote regeneration.
Target Audience
The primary target audience includes patients suffering from severe liver disease with limited treatment options, as well as healthcare providers seeking innovative solutions to address the critical need for effective liver therapies.
Features
- Subcutaneous implant containing lab-engineered liver tissue derived from human stem cells
- Designed for remote regeneration to safely supplement liver function
- Aims to reduce reliance on donor organs by providing a renewable treatment option
- Automated and scalable design for consistent and efficient production